Articles
FDA Matters: why orphan drugs are a key part of pharma’s future

FDA Matters: why orphan drugs are a key part of pharma’s fut...

Steven Grossman provides us with an insight into the inspiration behind his blog, FDA Matters, as well as his thoughts on the R&D of orphan drugs for rare diseases, in line with this month’s focus. The Orphan Drug Act was introduced in the United States in 1983, to encourage pharmaceutical companies to...

Articles
Market access challenges

Market access challenges

We interview Ulf Staginnus of Amgen on his view of challenges regarding pricing and market access. The changing European pricing environment presents a huge challenge to pharma and to gain a perspective on the scope of...

Articles
DTC budgets being trimmed substantially?

DTC budgets being trimmed substantially?

Rich Meyer questions whether DTC budgets are being substantially trimmed in the world of pharmaceutical marketing. A recent article about earnings for Pfizer indicated that “cost cutting” was a huge reason why the drug giant was improving its financial...

Sales & Marketing

Digital

Market Access

Editor's Picks

  1. ESMO26: Tango sees 82% ORR with combo in pancreatic cancer
  2. Roche offers $15bn for strategic-level deal with Hansoh
  3. ESMO26: Moderna, MSD reveal cancer jab data early after leak
  4. Clinical trial setup times fall sharply in UK
  5. Despite US policy changes, drug prices stay stubbornly high

Newsletters and Deep Dive
digital magazine

Oncology

more

Patients

more

R&D

more